Study biomarkers in kidney cancer and healthy people
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at blood or body measures called “biomarkers” to understand how lack of oxygen and body energy changes in clear cell kidney cancer. It compares people with kidney cancer to carefully matched healthy volunteers to see what patterns might help improve understanding or future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be either a person with clear cell renal cell carcinoma (ccRCC) or a matched healthy control volunteer
- If you’re a control volunteer: you must have no tumors anywhere (including in the blood system)
- If you’re a control volunteer: you must have no kidney problems like stones, diabetic kidney disease, nephritis, or very advanced kidney failure
- You must not have inflammation or major inflammatory illnesses in other parts of the body
- Your liver, kidney, and heart function must be normal
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding a gut health supplement (CBM588) to the immunotherapy drug pembrolizumab can help prevent kidney cancer from returning after surgery. It is for people with certain types of kidney cancer who have not had immunotherapy before.
This study looks for tiny substances in urine (called exosomes) to see if they can help identify clear cell kidney cancer. It compares urine samples from people having planned kidney surgery with people having surgery without a scheduled plan.
This trial tests a special PET scan to see if it can better find leftover kidney cancer after surgery compared to a standard CT scan. You may qualify if you had kidney cancer surgery within the last 4-16 weeks and are at high risk of the cancer coming back.
This study tests whether a simple blood test that tracks tumor DNA (called ctDNA) can help predict how well immunotherapy will work for people with non-clear cell kidney cancer. If you are about to start immunotherapy for advanced disease, this study could help your doctor better understand your treatment response.
This study follows people with newly diagnosed kidney cancer who have not started treatment. It tests whether a special blood test can monitor the cancer over time, alongside standard follow-up after planned surgery.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
Hear when a new Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.